Overall, these conflicting findings may be related to the diverging effects of OPG expression according to distinct breast cancer subtypes [31] and/or to different methods used for OPG expression analysis in different studies (e.g. quantitative PCR, immunohistochemistry). Here, TNFRSF11B is linked to breast carcinoma.